CONTEXT
MM
MULTIPLE MYELOMA (MM), CYTOKINE RELEASE SYNDROME


G protein–coupled receptor, class C group 5 member D (GPRC5D) is primarily expressed on malignant plasma cells in multiple myeloma (MM), and normal tissue expression is restricted to the hair follicle. We assessed the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.
Our results showed that the overall response rate was 91% in 33 patients with R/R MM, including 21 (64%) complete responses or better. No patients developed ≥ grade 3 cytokine release syndrome. The study demonstrates that anti-GPRC5D CAR T cell is another promising CAR-T therapy for patients with R/R MM.
Anti-GPRC5D CAR T-cell treatment is another effective CAR-T cell option, especially for R/R MM patients previously treated with anti-B-cell maturation antigen immunotherapy.**Relevance section written by G protein–coupled receptor, class C group 5 member D (GPRC5D), a type C 7-pass transmembrane receptor protein, is expressed on malignant and normal plasma cells at least 500-fold higher in bone marrow than that in peripheral plasma cells, and normal tissue expression is restricted to the hair follicle.On the basis of these findings, we conducted a phase Ⅱ clinical trial of anti-GPRC5D CAR T-cell therapy to observe the efficacy and safety in patients with R/R MM, including patients with previous anti-BCMA CAR T-cell therapy.